Zydus Lifesciences Limited has rescheduled its participation in the Motilal Oswal 22nd Annual Global Investor Conference to August 17, 2026. The pharmaceutical firm originally planned to engage with investors on August 18, 2026, as disclosed in an earlier intimation filed on August 10, 2026. This update ensures stakeholders are aware of the revised timeline for management interaction regarding strategic direction and business updates.

The revised disclosure was filed with both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) on August 12, 2026. The filing serves to correct the previous information and aligns market participants with the actual event schedule.

Event Details

The conference is organized by Motilal Oswal Financial Services. Zydus Lifesciences will now take part in the proceedings on August 17, 2026, instead of the previously announced August 18 date. The company did not specify a particular time slot or session format in the update.

Regulatory Compliance

The announcement was authorized by Dhaval Narendra Soni, Company Secretary and Compliance Officer of Zydus Lifesciences Limited. The filing carries membership number FCS7063 and was digitally signed on August 12, 2026, at 4:57 pm.

Zydus Lifesciences Limited maintains its registered office at 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. The company’s Corporate Identification Number (CIN) is L24230GJ1995PLC025878.

Zydus Life Sciences has shared key business expectations, highlighting that over two-thirds of its total revenue is anticipated to be derived from its branded portfolio. The company's U.S. business is targeted to grow from 10% to 15% by fiscal year end, underscoring a strategic focus on expanding its presence in one of the world's largest pharmaceutical markets.

Assertio Holdings Set to Boost Quarterly Revenue

A notable near-term catalyst for the company is the contribution from Assertio Holdings, which is projected to add $15 million to $20 million on a quarterly basis starting next quarter. This addition is expected to meaningfully support the company's U.S. revenue trajectory and strengthen its overall financial performance in the coming periods.

Consumer Wellness and Branded Business Outlook

The Consumer Wellness sector is expected to see strong double-digit growth for FY '27, reflecting the company's confidence in this segment's momentum. On the branded business front, Zydus Life Sciences has set an ambitious long-term target, aiming for EBITDA margins of 28%-30% plus over a five-year period.

The following table summarizes the key business targets and expectations shared by the company:

Strategic Focus on Branded and U.S. Markets

The company's guidance reflects a clear strategic emphasis on scaling its branded portfolio while simultaneously accelerating growth in the U.S. market. The targeted EBITDA margin range of 28%-30% plus for the branded business over five years signals a long-term commitment to improving profitability within this segment. The Consumer Wellness segment's projected double-digit growth for FY '27 further reinforces the breadth of the company's growth strategy across multiple business verticals.